<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00527865</url>
  </required_header>
  <id_info>
    <org_study_id>06-0082</org_study_id>
    <secondary_id>181-1-06-01</secondary_id>
    <nct_id>NCT00527865</nct_id>
    <nct_alias>NCT00718900</nct_alias>
  </id_info>
  <brief_title>Single Dose Escalating Study of DAS181 in Adults</brief_title>
  <official_title>Study 181-1-06-01 - Phase 1A Clinical Study With DAS181: Double-Blind, Randomized, Placebo-Controlled, Single Dose Escalating Study in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ansun Biopharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Ansun Biopharma, Inc.</source>
  <brief_summary>
    <textblock>
      This study will evaluate the safety, tolerability, and systemic exposure of an experimental&#xD;
      influenza (flu) treatment medication called DAS181. DAS181 is a dry powder that is&#xD;
      administered via oral inhalation using a special device. Study participants will include up&#xD;
      to 60 healthy, non-smoking males and females, ages 18-65. They will be given either DAS181 or&#xD;
      placebo. Participants will remain in the clinic overnight to be watched for health changes&#xD;
      for 24 hours after receiving the medication. Study procedures include: physical exams, chest&#xD;
      x-rays, ECGs, lung function tests, collection of blood and urine samples, and throat swabs.&#xD;
      Follow-up visits will occur on study days 2, 7, 14 +/- 1 day, and 30 +/- 2 days. Participants&#xD;
      will be involved in the study for up to 61 days, which includes the screening period.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this study is to investigate the safety, tolerability and pharmacokinetics&#xD;
      of a single dose of DAS181 encapsulated dry powder compared to placebo when administered by&#xD;
      oral inhalation using a dry powder inhaler in healthy adults. Primary study outcome measures&#xD;
      are the safety and tolerability of single-dose DAS181 treatment at 0.5 mg, 1.0 mg, 2.25 mg,&#xD;
      and 4.5 mg, as measured in the following parameters: adverse events, physical exam, vital&#xD;
      signs, hematology, clinical chemistry, blood coagulation, complement activation, haptoglobin&#xD;
      and immunogenicity, urinalysis, throat swab for bacterial culture, ECG, chest X-ray, and&#xD;
      spirometric lung function. Secondary outcome measures are the systemic exposure and&#xD;
      pharmacokinetic parameters of DAS181. This phase 1 study will be a double-blind, randomized,&#xD;
      placebo-controlled, single-dose escalation study conducted at Comprehensive Phase One Miramar&#xD;
      campus. Thirty-six to 60 healthy male and female volunteers, 18-65 years (inclusive), will be&#xD;
      enrolled in 4 separate steps. Each enrollment will recruit 9 subjects for one of the 4 dose&#xD;
      groups. Within each dose group, the participants will be randomly assigned to placebo or&#xD;
      DAS181, at 1:2 ratios. The subjects will receive a single-dose treatment by placebo (10.5 mg&#xD;
      lactose), or by DAS181 at one of 4 doses: 0.5 mg, 1.0 mg, 2.25 mg, and 4.5 mg. The subjects&#xD;
      will be screened and enrolled within 28 days prior to dosing of the study drug. The study&#xD;
      will be initiated with 0.5 mg dose. Escalation to the next dose will be contingent upon&#xD;
      meeting the dose escalation criteria after the study day 7 post dosing follow-up visit (Visit&#xD;
      4). The day of dosing is always defined as Day 0 (or study day 0), regardless of the step or&#xD;
      cohort. All future visits and time periods are referenced to the day of dosing.&#xD;
      Administration of DAS181 or placebo will be given under the supervision of the study staff.&#xD;
      Subjects will enter the inpatient clinic on day -1, the evening prior to dosing. Subjects&#xD;
      will remain in the inpatient clinic for 24 hours post exposure to be observed for signs of&#xD;
      adverse events (AEs). After the 24-hour inpatient observation period, participants will be&#xD;
      discharged if they are deemed healthy at that point. All subjects must come back for&#xD;
      follow-up visits on the following study days: 2, 7, 14 (±1 day), and 30 (±2 days).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of a single-dose of DAS181 treatment at 0.5 mg, 1.0 mg, 2.25 mg, and 4.5 mg.</measure>
    <time_frame>Duration of study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The pharmacokinetic parameters of DAS181.</measure>
    <time_frame>Pre-dosing, 1, 2, 4, 6, 8, 12 and 24 hours post dosing, Day 2, and Day 7</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 subjects DAS181 dosage 0.5 mg; 3 subjects placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 subjects DAS181 dosage 1.0 mg; 3 subjects placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 subjects DAS181 dosage 2.25 mg; 3 subjects placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 subjects DAS181 dosage 4.5 mg; 3 subjects placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DAS181</intervention_name>
    <description>DAS181 is formulated as dry powder and packaged in capsules containing DAS181. The delivered dose of DAS181 dry powder at each fill size is 0.5 mg, 1.0 mg, 2.25 mg, and 4.5 mg.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Capsules containing 10.5 mg of lactose will be supplied as placebo.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Healthy, non-smoking adult male and female volunteers between the ages of 18 and&#xD;
        65(inclusive)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Comprehensive Phase One</name>
      <address>
        <city>Miramar</city>
        <state>Florida</state>
        <zip>33025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2009</verification_date>
  <study_first_submitted>September 10, 2007</study_first_submitted>
  <study_first_submitted_qc>September 10, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 11, 2007</study_first_posted>
  <last_update_submitted>January 6, 2009</last_update_submitted>
  <last_update_submitted_qc>January 6, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 8, 2009</last_update_posted>
  <responsible_party>
    <name_title>Mang Yu</name_title>
    <organization>Nexbio, Inc</organization>
  </responsible_party>
  <keyword>Influenza, Flu, DAS181, Fludase</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

